The M&A and Life Sciences teams advised Centerview Partners in its role as financial advisor to RayzeBio, Inc. (Nasdaq: RYZB) in a definitive agreement for Bristol Myers Squibb (NYSE: BMY), through a subsidiary, to acquire RayzeBio for $62.50 per share in cash, for an approximate total equity transaction value of $4.1 billion.
Centerview Partners is a leading independent investment banking and advisory firm. The firm provides advice on mergers and acquisitions, financial restructurings, valuation, and capital structure to companies, institutions and governments. Since the founding of Centerview in 2006, the firm has advised on over $3 trillion of transactions.
RayzeBio is building a radiopharmaceutical therapeutics (RPT) company to treat various cancers, with its lead program in a Phase 3 clinical trial. RayzeBio has created a pipeline of multiple drug candidates in therapeutic areas with significant market opportunities. Much like antibody drug conjugates emerged as a new and transformative treatment modality in certain cancers, the company sees an opportunity for innovative radiopharmaceutical therapeutics to follow a similar path. RayzeBio believes its strategic investments in building a robust product pipeline, development capabilities, and manufacturing infrastructure position the company to be an industry-leading pioneer in the broad application of RPT for cancer.
The Goodwin team advising Centerview was led by Stuart M. Cable, Blake Liggio and James Ding.
For more information, please read the companies’ joint press release.